BUSINESS BRIEFING / PHARMACEUTICALS
Times Wire Reports
AstraZeneca and Merck & Co. said they would jointly develop a pair of drugs meant to hit cancer with a one-two punch, part of a growing trend of combination cancer treatments.
The companies, two of the world’s biggest drug makers, said they would combine efforts with Merck’s MK-2206 and AstraZeneca’s AZD6244, both of which are still in very early development.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
